| Dr Adesua Okupa Wejinya, BS, MD | |
|
700 S 52nd St, Rogers, AR 72758-8605 | |
| (479) 464-8887 | |
| Not Available |
| Full Name | Dr Adesua Okupa Wejinya |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 18 Years |
| Location | 700 S 52nd St, Rogers, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790812246 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KA0200X | Allergy & Immunology - Allergy | IN PROGRESS (Arkansas) | Secondary |
| 207K00000X | Allergy & Immunology | E-7110 (Arkansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hedberg Allergy And Asthma Center Pa | 3476454026 | 5 |
| Hedberg Allergy And Asthma Center Pa | 3476454026 | 5 |
News Archive
The survival rate for people who suffer out-of-hospital cardiac arrest in the United States is dismal — around 5 percent — say researchers at the University of Alabama at Birmingham.
SDI (Strategic Diagnostics Inc.), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" initiative (CPTC: http://proteomics.cancer.gov).
Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke.
"Publicly, consumer and patient advocates continue to cheer wildly for last year's health care law. Behind the scenes, however, some worry that they are losing a few key battles to the insurance and business communities.
› Verified 7 days ago
| Entity Name | Hedberg Allergy And Asthma Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295820918 PECOS PAC ID: 3476454026 Enrollment ID: O20040116000205 |
News Archive
The survival rate for people who suffer out-of-hospital cardiac arrest in the United States is dismal — around 5 percent — say researchers at the University of Alabama at Birmingham.
SDI (Strategic Diagnostics Inc.), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" initiative (CPTC: http://proteomics.cancer.gov).
Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke.
"Publicly, consumer and patient advocates continue to cheer wildly for last year's health care law. Behind the scenes, however, some worry that they are losing a few key battles to the insurance and business communities.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adesua Okupa Wejinya, BS, MD 700 S 52nd St, Rogers, AR 72758-8605 Ph: (479) 464-8887 | Dr Adesua Okupa Wejinya, BS, MD 700 S 52nd St, Rogers, AR 72758-8605 Ph: (479) 464-8887 |
News Archive
The survival rate for people who suffer out-of-hospital cardiac arrest in the United States is dismal — around 5 percent — say researchers at the University of Alabama at Birmingham.
SDI (Strategic Diagnostics Inc.), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" initiative (CPTC: http://proteomics.cancer.gov).
Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke.
"Publicly, consumer and patient advocates continue to cheer wildly for last year's health care law. Behind the scenes, however, some worry that they are losing a few key battles to the insurance and business communities.
› Verified 7 days ago
Dr. Jenny Miranda Campbell, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 700 S 52nd St, Rogers, AR 72758 Phone: 479-464-8887 Fax: 479-464-9949 | |
Dr. Curtis Lars Hedberg, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 700 S 52nd St, Rogers, AR 72758 Phone: 479-464-8887 Fax: 479-464-9949 |